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Objectives: To describe prospectively the evolution of interstitial lung disease
(ILD) in RA treated with modifying antirheumatic drugs (DMARDs) in clinical
practice.
Methods : Design: Multicenter prospective observational cohort. Patients:
Patients with RA (ACR/EULAR 2010 criteria) and ILD (American Thoracic Society)
from different centres of Málaga, Valme Hospital of Sevilla and Virgen Nieves of
Granada were included. Protocol: All patients with RA and ILD who visited clinic
from 2015 to 2017 were recruited. They were reviewed according to a predeter-
mined protocol for data collection. Resolution Computed Tomography (HRCT),
Pulmonary function test (PFT) and echocardiogram were requested for all
patients who did not have it in the last year. This visit was marked as v0 (index
date). At 12 months (v12) the joint assessment (DAS28), echocardiogram, PTF
and HRCT were again evaluated. HRCT’s were assessed by the same radiolog-
ist. Outcomes: At v12:(1improvement (ie improvement in FVC 10% or DLCO
15% and no radiological progression),2 non-progression (stabilisation or
improvement in FVC £10% or DLCO <15% and no radiological progression),(3
progression (worsening of FVC >10% or DLCO >15% and radiological progres-
sion), or4 death due to ILD. Variables: Description of ILD type and lung function by
PTF, HRCT. Presence of PTH by echocardiogram and dyspnoea. Disease activity
by DAS28-ESR;Adverse events during the follow-up period. Statistical analysis:
Descriptive analysis and Wilcoxon or T test between the v0 and v12. One factor
ANOVA between sDMARD, bDMARD and combination therapy groups.
Results: The main characteristics at V0 of the patients (n=41) are shown in the
table 1. Nine patients (21.9%) received a sDMARDs with a bDMARDs;25 patients
(60.9%) monotherapy with sDMARD and 7 (17.0%) monotherapy with bDMARDs
(table 1). Nine patients (21.9%) had improvement (2 with MTX, 1 with MTX +HCQ,
2 with RTX, 2 HCQ +RTX, 1 MMF +RTX and 1 with ABA); 24 patients (58.5%)
remained stable (6 with MTX, 6 with LFN, 3 with HCQ, 1 AZA, 1 SSZ, 1 MMF, 1
TCZ, 2 ABA, 1 MTX +ETN, 1 HCQ +RTX, 1 HCQ +ADA, 1 RTX +MMF); and 7
(17.0%) got worse of ILD (2 with MTX developed lung nodules not known, 2 with
LFN, 1 with LFN +IFX, 1 with ETN +MTX and 1 with SSZ). One patient died due to
respiratory infection (with RTX). Two patients developed PPH. We did not find sig-
nificant differences between Vo DAS28 and v12 (2.61 [0.74] vs 2.54 [1.12];
p=0.684) or in HAQ (1.12 [0.89] vs 1.23 [0.73],p=0.368). There were no significant
differences in PTF, HRCT or DAS28 between sDMARD, bDMARD and combina-
tion therapy groups. During the follow-up period 27 patients had infections, the
majority (53.7%) respiratory infection.
Conclusions: Most patients with RA and ILD who are receiving treatment with
DMARD (80.5%) remained stable or improved after at least one year of both syn-
thetic and biological DMARD treatment. More prospective studies are necessary
to identify the influence of DMARDs in this evolution.
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Background : Rheumatoid arthritis (RA) associates with accelerated atheroscle-
rosis and high cardiovascular mortality. Cardiovascular risk assessment in RA pts
with comorbid hypertension (HT) is do not fully reflected by traditional risk scales,
thus additional factors searching is required.
Objectives: We aimed to estimate the adiponectin level, insulin resistance, endo-
thelial function in RA females with comorbid HT and its relationship with subclini-
cal manifestations of atherosclerosis.
Methods: The study included 82 RA females with low disease activity and comor-
bid HT (mean age of 54.6 [49.7; 62.5] years) and 40 HT females without RA (con-
trol group). All pts received stable therapy of RA more than 6 months. Pts with
coronary artery disease were excluded. The risk of fatal cardiovascular disease
was calculated using mSCORE. RA disese activity was measured using DAS28
scale. Carotid ultrasound detection and endothelial-dependent flow mediated vas-
odilatation (EDVD) by Celermajer method were performed. The levels of adipo-
nectin, insulin were measured using ELISA kit test, insulin resistance was
estimated using HOMA2 index.
Results: Endothelial dysfunction was established in the majority of main group
patients – 61 (74.4%), insulin resistance – in 70 (85.4%), elevated levels of adipo-
nectin – in 35 (42.7%). Hypertensive females with RA had significantly higher adi-
ponectin, insulin, insulin resistance levels compare to control (p<0.05).
Subclinical manifestations of atherosclerosis were established in 64 (78.0%) HT
females with RA and 10 (50%) control group pts. While the median cardiovascular
risk level was 4.2 [2.7; 6.5]% matched by mSCORE. The presence of atheroscler-
otic plaques in HT females with RA was associated with age (OR=1.242, p=0.004,
95% CI 1.007–1.78), glucocorticosteroid therapy >3 months (OR=1.56, p=0.001,
95% CI 1.22–2.45), endothelial dysfunction (OR=3.584, p=0.001, 95% CI 1.71–
4.723), insulin resistance (OR=1.684, p=0.011, 95% CI 1.22–2.74), abnormal adi-
ponectin level (OR=1.71, p=0.028, 95% CI 1.17–2.43). AUROC index for prog-
nostic role of adiponectin and HOMA2 in subclinical atherosclerosis develop were
0.79 (95% CI 0.64–0.95; p<0.05) and 0.76 (95% CI 0.61–0.92; p<0.05) respec-
tively, that indicate a good quality of diagnostic models.
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Conclusions: Hypertensive females with rheumatoid arthritis are characterised
by higher frequency of insulin resistance, endothelial dysfunction, adiponectin
level changes which associates with subclinical atherosclerosis manifestations.
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Background: Patients often describe pain as the most important symptom of RA.
Despite advances in RA therapy to improve disease control, some patients con-
tinue to have significant pain1,2. The relative impact of pain on RA patients’ evalu-
ations of overall health and RA-specific global assessments is unknown.
Objectives: Determine the relative role of pain in RA patients’ health
assessments.
Methods: Data derived from the Forward (The National Databank for Rheumatic
Diseases) longitudinal cohort, collected January-May 2017. Respondents
(n=5471) have rheumatologist-confirmed RA. Two health assessments were
examined:1 overall satisfaction with health (SAT) measured by the item: “How sat-
isfied are you with your health now?” with responses of very unsatisfied to very
satisfied; and2 patient global assessments of RA impact (GBL) measured using a
numeric rating scale (NRS): “Considering all the ways that your RA affects you,
rate how you are doing on a scale of 0–10, where 0=very well and 10=very poor.”
For regression analyses, SAT was dichotomized as “very satisfied” or “somewhat
satisfied” vs. other responses. Current pain severity was rated on an NRS from 0
(no pain) to 10 (extreme pain). Spearman correlations examined the association
of pain with SAT and GBL. Initial multiple regression analyses (table 1, Model 1)
examined the following as predictors of SAT and GBL: age, sex, education, dis-
ease duration, obesity (BMI 30), conventional and biologic DMARD use, Rheu-
matic Disease Comorbidity Index3 (RDCI), self-report of depression, fatigue, and
functional limitations (Health Assessment Questionnaire [HAQ] score). Follow-up
models (Model 2) added pain to determine its relative independent role in health
assessments.
Results: The sample was 84% female, mean age 65 years, mean RA duration 22
years. 53% were satisfied with their health, and mean GBL was 3.6±2.5. Mean
pain severity rating was 3.8±2.8. Correlations of pain with SAT and GBL were
0.58 and 0.71, respectively (each p<0.0001). Regression models predicting both
SAT and GBL improved with the addition of pain (table 1). Pain was significantly






Pain 0.81 (0.79, 0.84)*
Model R2 0.37 0.40
Global assessment of RA
Pain 0.33 (<0.0001)†
Model R2 0.51 0.57
*Odds ratio (95% CI)
† b (p-value)
Regression models included age, sex*, education, disease duration, obesity,
medications, RDCI, depression, fatigue*, and HAQ*. Variables noted with asterisk
were also statistically significant (p<0.05) in both final models.
Conclusions: Pain plays a critical role in RA patients’ assessments of general
and RA-specific health. Analyses suggest that pain may be more important to RA
global assessments than to overall health satisfaction, though the clinical rele-
vance of this difference is not known. RA global assessments are included in
some indices of disease activity. Future research should focus on distinguishing
between non-inflammatory and inflammatory causes, which may lead to more
accurate assessment of RA disease activity.
REFERENCES:
[1] Lee YC, et al. Arthritis Res Ther 2011;13:R83.
[2] Altawil R, et al. Arthritis Care Res 2016;68:1061.
[3] England BR. Arthritis Care Res 2015;6:865.
Disclosure of Interest: P. Katz Grant/research support from: Eli Lilly and Co, Y.
Lee Grant/research support from: Eli Lilly and Co, A. Quebe Employee of: Eli Lilly
and Co, L. Sun Employee of: Eli Lilly and Co, H. Patel Employee of: Eli Lilly and
Co, C. Gaich Employee of: Eli Lilly and Co, N. Boytsov Employee of: Eli Lilly and
Co, K. Michaud Grant/research support from: Eli Lilly and Co
DOI: 10.1136/annrheumdis-2018-eular.2740
FRI0081 THE IMPORTANCE OF TRANSFERRIN SATURATION,
SERUM FERRITIN, LOG FERRITIN AND TRANSFERRIN/
LOG FERRITIN IN DIFFERENTIATING IRON DEFICIENCY
ANAEMIA FROM ANAEMIA OF CHRONIC DISEASE IN
RHEUMATOID ARTHRITISPATIENTS
R.A. Abdel Noor1, M.H. Abu-Zaid2, S.A. Elshweikh3, E.S. Rabee4, G.E. Khedr5.
1Internal Medicine and Rheumatology; 2Physical medicine, Rheumatology and
Rehabilitation; 3Internal Medicine and Hematology; 4Clinical pathology, Faculty of
Medicine, Tanta University; 5Clinical pathology, Tanta Cancer Center, Tanta, Egypt
Background: The most common types of anaemia in rheumatoid arthritis (RA)
are iron deficiency anaemia (IDA) and anaemia of chronic disease (ACD). The dif-
ferentiation between both is very important and challenging.
Objectives: is to select the most simple, cheap, accurate method differentiate
IDA from ACD in RA patients.
Methods: This case control study was carried out on 80 RA patients. Group I 40
RA patients with anaemia Group II 40 RA patients without anaemia, complete
blood count, assessment of disease activity using DAS 28 score, serum iron, total
iron binding capacity (TIBC) “transferrin level”, transferrin saturation (TSAT),
serum ferritin, log ferritin and transferrin/log ferritin were tested, then we divided
the patients in group 1 into 2 subgroups according to TSAT : group Ia (RA patients
with anaemia and low TSAT) and group Ib (RA patients with anaemia and normal
TSAT) and we compared the parameters.
Results: There was a statistically significant difference between anaemic and
non anaemic RA patients as regard serum iron level and transferrin saturation and
there was no significant difference as regard serum ferritin, log ferritin, transferrin
and transferrin/log ferritin. Among the anaemic group (67.5%) had low TSAT
(IDA) and only (32.5%) had normal TSAT (ACD). In these 2 subgroups there was
no significant differences as regard DAS28 score, blood indices, serum ferritin
and transferrin/log ferritin) except Log ferritin and there was positive correlation
between TSAT and (ferritin and log ferritin) and significant negative correlation
between TSAT and transferrin/log ferritin.








DAS-28 2.99±1.07 2.35±0.77 0.002*
Hb (g/dl) 9.62±0.96 12.95±0.64 <0.0001*
MCV (fl) 79.71±7.29 83.0±9.34 0.083
MCH (pg/cell) 26.06±4.05 28.05±2.66 0.006*
MCHC (g/dl) 31.1±2.21 31.23±2.38 0.8
Serum iron (mg/ml) 0.66±0.37 0.89±0.38 0.0076*
Serum ferritin (ng/ml) 83.02±93.08 84.87±86.82 0.927
TIBC (mg/ml) 3.94±1.06 3.71±0.59 0.23
TSAT (%) 17.7±10.6 24.73±11.36 0.0054*




Figure 1 Correlation between TSAT and (serum ferritin, log ferritin and Transfer-
rin/Log ferritin)









is: first published as 10.1136/annrheum
dis-2018-eular.2341 on 12 June 2018. Downloaded from
 
